Research Article| Volume 312, ISSUE 1-2, P142-145, January 15, 2012

Download started.


Electrophysiological evaluation of spinocerebellar ataxias 1, 2 and 3

Published:September 01, 2011DOI:



      Subclinical neuropathy is an important feature of spinocerebellar ataxias (SCA) but the true prevalence and electrophysiological characteristics in genetically proven patients of SCA 1, 2 and 3 are largely unknown.


      We prospectively compared the electrophysiological characteristics of neuropathy in 61 genetically confirmed cases of SCA (SCA1=28, SCA2=16 and SCA3=17). Nerve conduction studies were performed in at least one sensory and one motor nerve, in right upper and lower limb using standard methods.


      The mean age of patients and duration of illness were comparable among SCA groups (mean age (years): SCA1—34.1±12.7, SCA2—35.2±13.9 and SCA3—38.1±11.3; mean duration (years): SCA1—5.4, SCA2—6.1, and SCA3—4.4). Electrophysiological evidence of neuropathy was highest in SCA1 (96.4%), followed by SCA3 (94.1% and SCA2 (87.5%). A mixed sensorimotor neuropathy was commonly observed in all the subgroups (SCA1—78.6%, SCA2—50%, and SCA3—41.2%). Pure sensory neuropathy was most common in SCA3 (55.9%), followed by 31.3% in SCA2 and 17.9% in SCA1. Pure motor neuropathy was uncommon (6.3% in SCA2 and none in SCA1 and SCA3).


      Electrophysiological evidence of mixed sensorimotor and pure sensory neuropathy is seen in all the three subtypes of SCAs, while pure motor neuropathy is distinctly uncommon.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of the Neurological Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Harding A.E.
        Classification of the hereditary ataxias and paraplegias.
        Lancet. 1983; 1: 1151-1155
        • Harding A.E.
        Clinical features and classification of inherited ataxias.
        Adv Neurol. 1993; 61: 1-14
        • Klockgether T.
        • Ludtke R.
        • Kramer B.
        • et al.
        The natural history of degenerative ataxia: a retrospective study in 466 patients.
        Brain. 1998; 121: 589-600
        • Abele M.
        • Bürk K.
        • Andres F.
        • et al.
        Autosomal dominant cerebellar ataxia type I:nerve conduction and evoked potential studies in families with SCA1, SCA2 and SCA3.
        Brain. 1997; 120: 2141-2148
        • van de Warrenburg B.P.
        • Notermans N.C.
        • Schelhaas H.J.
        • et al.
        Peripheral nerve involvement in spinocerebellar ataxias.
        Arch Neurol. 2004 Feb; 61: 257-261
        • Klockgether T.
        • Schöls L.
        • Abele M.
        • et al.
        Age related axonal neuropathy in spinocerebellar ataxia type 3/Machado–Joseph disease (SCA3/MJD).
        J Neurol Neurosurg Psychiatry. 1999; 66: 222-224
        • Kubis N.
        • Dürr A.
        • Gugenheim M.
        • et al.
        Polyneuropathy in autosomal dominant cerebellar ataxias: phenotype–genotype correlation.
        Muscle Nerve. 1999; 22: 712-717
        • Trouillas P.
        • Takayanagi T.
        • Hallett M.
        • et al.
        International Cooperative Ataxia Rating Scale for pharmacological assessment ofthe cerebellar syndrome, The Ataxia Neuropharmacology Committee of the World Federation of Neurology.
        J Neurol Sci. 1997 Feb 12; 145: 205-211
        • Carenini L.
        • Finocchiaro G.
        • Di Donato S.
        • Visciani A.
        • Negri S.
        Electromyography and nerve conduction study in autosomal dominant olivopontocerebellar atrophy.
        J Neurol. 1984; 231: 34-37
        • Bauer P.O.
        • Nukina N.
        The pathogenic mechanisms of polyglutamine diseases andcurrent therapeutic strategies.
        J Neurochem. 2009; 110 (Sep,Epub 2009 Jul 23. Review): 1737-1765